our therapy - Novocure

We have revised our Privacy Policy that is in effect as of May 25, 2018. Please click here to access it.

about us

corporate timeline Professor Yoram Palti founded Novocure in 2000. We have since accomplished many significant milestones.

leadership Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries.

corporate presentation We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields.

ESG report Corporate social responsibility is important to us, and patients remain at the heart of the work we do every day.
our therapy
our pipeline

clinical trials Our mechanism of action is broadly applicable across a variety of solid tumors.

novocuretrial.com The science of Tumor Treating Fields extends beyond glioblastoma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer.
patient-forward
news and media

press releases

press kits

media gallery

featured stories
investor relations

press releases

corporate presentation

events

annual reports

sec filings

stock information

corporate governance

faq

email alerts

NASDAQ: current stock price

218.04

-4.27

last update 6/18/2021 16:00pm
careers

our locations

current job listings

mechanism of action

Tumor Treating Fields, or TTFields, are low intensity, alternating electric fields that disrupt cell division through physical interactions with key molecules during mitosis in solid tumor cancers.

cancer cell

structures align within the cell

electric fields interfere with cell division

cell death

delivery method

Click the link below to discover our Tumor Treating Fields delivery system.

LEARN MORE

treating cancer with electric fields

There are two well-established physical processes that TTFields use to disrupt dividing cells, dipole alignment and dielectrophoresis.

Watch Video

about us
- corporate timeline Professor Yoram Palti founded Novocure in 2000. We have since accomplished many significant milestones.
- leadership Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries.
- corporate presentation We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields.
- ESG report Corporate social responsibility is important to us, and patients remain at the heart of the work we do every day.
our therapy
our pipeline
- clinical trials Our mechanism of action is broadly applicable across a variety of solid tumors.
- novocuretrial.com The science of Tumor Treating Fields extends beyond glioblastoma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer.
patient-forward
news and media
investor relations
careers
- our locations
- current job listings